Want to see RCKT full AI Analyst Report?
Top Page
Rocket Pharmaceuticals
(NASDAQ:RCKT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.00
▲(2.30% Upside)
Action:Reiterated
Date:07/04/26
The score is primarily held back by weak financial performance (no revenue, sizable losses, and significant negative free cash flow). Technicals are supportive with price above major moving averages and positive MACD, but overbought readings (RSI/Stoch) temper the setup. Valuation remains constrained by negative earnings (negative P/E) and no indicated dividend yield.
Positive Factors
Large non-dilutive cash infusion extends runway
The $180M voucher sale meaningfully strengthens liquidity and extends the funding runway into Q2 2028. This non-dilutive capital reduces near-term financing pressure, allowing multi-year clinical advancement of gene-therapy programs without immediate equity issuance, improving medium-term program optionality.
Negative Factors
Zero revenue; pre-commercial risk
Rocket remains pre-commercial with no product revenue, so its value depends on successful late-stage trials, approvals and commercialization. That structural revenue absence means long lead times to positive cash flow and sustained execution risk across R&D, manufacturing scale-up, and market access.
Read all positive and negative factors
Positive Factors
Negative Factors
Large non-dilutive cash infusion extends runway
The $180M voucher sale meaningfully strengthens liquidity and extends the funding runway into Q2 2028. This non-dilutive capital reduces near-term financing pressure, allowing multi-year clinical advancement of gene-therapy programs without immediate equity issuance, improving medium-term program optionality.
Read all positive factors
Rocket Pharmaceuticals (RCKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$365.80M
Dividend YieldN/A
Average Volume (3M)2.79M
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth28.56%
CountryUS
Employees299
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding109,193,550
10 Day Avg. Volume3,528,875
30 Day Avg. Volume2,793,659
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.41
Price to Sales (P/S)0.00
P/FCF Ratio-2.05
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.35
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$11.80Price Target Upside201.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$2.29M
Rocket Pharmaceuticals Business Overview & Revenue Model
Company Description
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multipl...
How the Company Makes Money
null...
Rocket Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.68M | -11.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -194.47M | -210.21M | -247.49M | -236.62M | -213.69M | -157.81M |
| Net Income | -209.38M | -223.12M | -258.75M | -245.59M | -221.86M | -169.07M |
Balance Sheet | ||||||
| Total Assets | 285.41M | 330.45M | 527.70M | 566.34M | 551.81M | 497.02M |
| Cash, Cash Equivalents and Short-Term Investments | 144.38M | 188.93M | 372.34M | 373.18M | 356.39M | 388.74M |
| Total Debt | 24.76M | 24.88M | 25.50M | 25.04M | 22.87M | 22.60M |
| Total Liabilities | 47.37M | 53.23M | 64.47M | 73.77M | 62.12M | 42.30M |
| Stockholders Equity | 238.04M | 277.22M | 463.23M | 492.57M | 489.69M | 454.72M |
Cash Flow | ||||||
| Free Cash Flow | -179.79M | -190.45M | -215.59M | -211.39M | -186.76M | -128.88M |
| Operating Cash Flow | -179.63M | -190.01M | -209.72M | -194.92M | -178.14M | -121.16M |
| Investing Cash Flow | 179.25M | 103.77M | 131.71M | -98.07M | -69.33M | 18.85M |
| Financing Cash Flow | 155.00K | 148.00K | 185.74M | 208.40M | 155.29M | 37.68M |
Rocket Pharmaceuticals Technical Analysis
Positive
3.91
Price Trends
3.24
Positive
3.66
Positive
3.55
Positive
Market Momentum
0.12
Negative
70.78
Negative
84.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCKT, the sentiment is Positive. The current price of 3.91 is above the 20-day moving average (MA) of 3.10, above the 50-day MA of 3.24, and above the 200-day MA of 3.55, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 70.78 is Negative, neither overbought nor oversold. The STOCH value of 84.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RCKT.
Rocket Pharmaceuticals Risk Analysis
Rocket Pharmaceuticals disclosed 3 risk factors in its most recent earnings report. Rocket Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our strategic restructuring may not result in the savings we anticipate, could result in total costs and expenses that are greater than expected and could disrupt our operations Q2, 2025
2.
We are and may continue to be targets of securities-related class action and derivative lawsuits and defending against these claims could result in substantial costs and divert management time and resources and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, may be costly to defend or pursue and are uncertain in their outcome Q2, 2025
Rocket Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $679.59M | -4.89 | -36.83% | ― | 383560.87% | 20.87% | |
52 Neutral | $365.80M | ― | -70.79% | ― | ― | 28.56% | |
52 Neutral | $420.53M | -1.45 | -128.53% | ― | 928.46% | -21.39% | |
52 Neutral | $1.16B | -19.75 | -73.23% | ― | ― | -42.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $642.22M | ― | -36.61% | ― | -75.91% | -173.33% | |
45 Neutral | $549.73M | -47.83 | -4.21% | ― | 121.11% | 80.74% |
* Healthcare Sector Average
RCKT
Rocket Pharmaceuticals
3.84
1.03
36.65%
ASMB
Assembly Biosciences
27.74
9.18
49.46%
CTMX
CytomX Therapeutics
3.82
1.45
61.18%
AUTL
Autolus Therapeutics
1.58
-0.68
-30.09%
FDMT
4D Molecular Therapeutics
13.00
9.05
229.11%
DRTS
Alpha Tau Medical Ltd
13.23
9.94
302.13%
Rocket Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Rocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
Positive
Jun 12, 2026
On June 10, 2026, Rocket Pharmaceuticals completed the sale of its FDA-issued Rare Pediatric Disease Priority Review Voucher, originally granted with the approval of its gene therapy KRESLADI for severe leukocyte adhesion deficiency-I, to a large ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
Positive
May 21, 2026
Rocket Pharmaceuticals held its 2026 Annual Meeting of Stockholders on May 20, 2026, with approximately 74% of eligible common shares represented in person or by proxy. Stockholders elected seven directors to the board, including Gaurav Shah, M.D....
Business Operations and StrategyPrivate Placements and Financing
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
Positive
Apr 28, 2026
On April 26, 2026, Rocket Pharmaceuticals entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher that it was awarded after the U.S. Food and Drug Administration granted accelerated approval to its gene therapy...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.